



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

September 08, 2009 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:20 - 7:20**
 - No follow-up items
- 6. Clinical Update: Drug Reviews** **7:20 – 8:10**

(Public comment prior to Board action)

Abbreviated New Drug Reviews

 - Apriso[®] (mesalamine) Extended Release Capsule
 - Kapidex[®] (dexlansoprazole) Capsule
 - Moxatag[®] (amoxicillin) Extended Release Tablet
 - Prandimet[®] (repaglinide/metformin) Tablet
 - Prilosec[®] (omeprazole magnesium) Delayed Release Suspension Powder Packet

Full New Drug Reviews

 - Banzel[®] (rufinamide) Tablet
 - Uloric[®] (febuxostat) Tablet
 - Vectical[®] (calcitriol) Topical Ointment
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:10 – 8:30**

(Public comment prior to Board action)

 - Botulinum Toxins
 - Gastrointestinals: Proton Pump Inhibitors
 - Specialty Pharmacy Expansion – Select Oral Oncology
 - Synagis[®] – New AAP guidelines (see RetroDUR)
- 8. Drug Classes – Annual Review** **8:30 – 8:30**

(Public comment prior to Board action)

 - No class reviews this month

- 9. RetroDUR** **8:30 - 8:45**
- Synagis®
- 10. New Drug Product Plan Exclusions (Consent Agenda Topic)** **8:45 - 8:45**
- 11. Updated New-to-Market Drug Monitoring Log (Consent Agenda Topic)** **8:45 - 8:45**
- Now on OVHA website
- 12. General Announcements** **8:45 – 8:55**
- Selected FDA Safety Alerts**
- Acetaminophen – liver injury – FDA safety campaign
 - Colchicine – now FDA approved, drug interactions, safety concerns
 - Ibuprofen – topical drug products
 - Leukotriene Inhibitors – neuropsychiatric events
 - Orlistat – liver injury
 - Propoxyphene – fatal overdoses
 - Stimulant Medication in Children with ADHD
 - Tumor Necrosis Factor (TNF) Blockers – increased risk of lymphoma and other cancers
 - Xolair® – ongoing safety review
- 13. Adjourn** **9:00**